Biotechnology Today
more-
Fresenius Medical Care taps former Philips exec to take the reins after CEO’s retirement
The year is still young, but Fresenius Medical Care, for one, is already looking ahead…
Elligo, WHYZE join forces to break down barriers for clinical trials
Bancel has ‘never been as busy’ amid M&A talks as Moderna preps for life after COVID
FDA approves Orthofix’s ultrasonic bone fracture healing system
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures
Markets
more-
Weekly Market Review – May 14, 2022
Stock Markets Since the markets hit an all-time high on the first trading day of…
Bio Space
more
A fix to PI3K cancer drugs’ immune toxicity? Lessons from an Amgen candidate
The FDA recently put the spotlight on the concerning side…
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug
Apnimed isn’t resting on its laurels. A year after its…
Biogen shoves Aduhelm to the side. It’s time for lecanemab
Biogen’s CEO is out. Aduhelm is, essentially, on its last…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
Fresenius Medical Care taps former Philips exec to take the reins after CEO’s retirement
Elligo, WHYZE join forces to break down barriers for clinical trials
Bancel has ‘never been as busy’ amid M&A talks as Moderna preps for life after COVID
FDA approves Orthofix’s ultrasonic bone fracture healing system
A fix to PI3K cancer drugs’ immune toxicity? Lessons from an Amgen candidate
Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug
Biogen shoves Aduhelm to the side. It’s time for lecanemab
Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug vision
All Takeda wants for its billion-dollar gene therapy spending spree is functional cures
Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartis